These findings underscore the critical contribution of the tumor microenvironment to therapy resistance and highlight metabolic vulnerabilities, such as SREBP-1 activation and ferroptosis evasion, as promising targets to overcome CAF-mediated protection. This evidence concerns the gene SREBF1 and neoplasm.